1. Phylogeny  
   Cyclin-dependent kinase 3 (CDK3), also known as cell division protein kinase 3, is encoded by the gene CDK3/CDKN3 and is a conserved member of the cyclin‐dependent kinase family. It is classified within the CMGC branch of the human kinome—a group that comprises cyclin-dependent kinases along with mitogen-activated protein kinases (MAPKs), glycogen synthase kinases (GSKs), and CDK-like kinases (CLKs) (alrouji2025mechanisticrolesof pages 1-2, chowdhury2023cmgckinasesin pages 1-2). Comparative sequence analyses reveal that CDK3 possesses the conserved catalytic motifs, including the glycine-rich loop and the PSTAIRE helix that is essential for its interaction with regulatory cyclins such as cyclin-C, echoing characteristics common to other cell cycle regulators like CDK1, CDK2, CDK5 and CDK6 (nilapwar2009characterizationandexploitation pages 47-51, dowerah2025identificationofeffective pages 68-71). Such motifs have been maintained since the Last Eukaryotic Common Ancestor (LECA), underscoring the evolutionary pressure to preserve mechanisms that enable tight control of the cell cycle. Orthologs of CDK3 can be found broadly across eukaryotes—from unicellular organisms to mammals—which highlights its fundamental role in governing transitions between quiescent and proliferative states (pluta2024cyclin‐dependentkinasesmasters pages 1-3, chowdhury2023cmgckinasesin pages 2-4). This deep conservation suggests that CDK3’s functional capacity in promoting cell cycle re-entry is a core characteristic maintained throughout evolution (alrouji2025mechanisticrolesof pages 1-2).
2. Reaction Catalyzed  
   CDK3 acts as an ATP-dependent serine/threonine-protein kinase, catalyzing the transfer of a phosphate group from ATP to specific serine or threonine residues on target substrates. The chemical reaction it mediates can be generalized by the equation: ATP + [protein]–(Ser/Thr) → ADP + [protein]–(phospho-Ser/Thr) + H⁺ (adams2001kineticandcatalytic pages 2-3, fischer2004thedesignof pages 1-2). In its catalytic cycle, CDK3 binds ATP and, in the presence of its requisite divalent metal ion cofactor, facilitates the nucleophilic attack by the hydroxyl group of the substrate’s serine or threonine residue. This mechanism involves kinetic steps whereby the formation of an enzyme–ATP–substrate complex is followed by phosphoryl transfer and subsequent release of ADP and the phosphorylated substrate. Among the confirmed physiological substrates for CDK3 are histone H1, activating transcription factor 1 (ATF1), retinoblastoma protein (RB1) and CABLES1 (alrouji2025mechanisticrolesof pages 1-2, pellarin2025cyclindependentproteinkinases pages 51-52). The phosphorylation of histone H1 may contribute to chromatin remodeling required for transcriptional changes during cell cycle re-entry, while phosphorylation of ATF1 is known to trigger its transactivation and augment its transcriptional activity, thereby promoting cell proliferation and transformation. Crucially, phosphorylation of RB1 by the CDK3/cyclin-C complex is essential for the G0-to-G1 transition as it leads to the inactivation of RB1, resulting in the subsequent activation of E2F transcription factors that drive the expression of genes necessary for S phase progression (alrouji2025mechanisticrolesof pages 1-2, pellarin2025cyclindependentproteinkinases pages 51-52). Additionally, phosphorylation events mediated by CDK3 may also contribute to G1-S progression in an RB1-independent fashion through the activation of E2F1, E2F2 and E2F3, further integrating cell cycle signals with transcriptional control.
3. Cofactor Requirements  
   The enzymatic activity of CDK3, similar to most serine/threonine kinases, is strictly dependent on the availability of ATP and the binding of divalent metal ions. Magnesium (Mg²⁺) is the principal cofactor that binds ATP and stabilizes its phosphate groups, ensuring the correct orientation and reactivity required for the phosphotransfer reaction (chowdhury2023cmgckinasesin pages 2-4, adams2001kineticandcatalytic pages 2-3). This Mg²⁺ ion not only aids in the binding of ATP within the conserved active site but also significantly influences the reaction kinetics by coordinating with catalytic residues, thus facilitating the efficient transfer of the phosphate group to the substrate. Although other divalent ions such as manganese (Mn²⁺) have been known to partially support kinase activity in in vitro assays, Mg²⁺ remains the physiologically relevant metal ion for CDK3 activity (fischer2004thedesignof pages 1-2). Furthermore, the local concentration of ATP and Mg²⁺ in the cell can modulate the kinase activity of CDK3, fine-tuning its function during specific cell cycle phases when rapid phosphorylation of key substrates is required.
4. Substrate Specificity  
   CDK3 exhibits a substrate specificity that is essential for its roles in driving cell cycle transitions and regulating transcription. Among its well-characterized substrates are histone H1, ATF1, the retinoblastoma protein (RB1), and CABLES1 (alrouji2025mechanisticrolesof pages 1-2, pellarin2025cyclindependentproteinkinases pages 2-4). Phosphorylation of histone H1 is thought to influence chromatin structure and thereby affect gene accessibility necessary for cell cycle progression. When CDK3 phosphorylates ATF1, the modification enhances ATF1’s transactivation and transcriptional functions, leading to the upregulation of proliferative and transformation-associated genes (pellarin2025cyclindependentproteinkinases pages 2-4). One of the critical functions of CDK3 is the phosphorylation of RB1, which results in the attenuation of RB1’s ability to repress E2F transcription factors. This event is pivotal for the transition of cells out of the quiescent G0 phase into the G1 phase and further supports progression into the S phase (pellarin2025cyclindependentproteinkinases pages 51-52, chowdhury2023cmgckinasesin pages 4-6). In addition, CDK3 is believed to target specific serine/threonine residues within a proline-directed context—the so-called S/T-P motif—a common recognition element among CDKs that aids in substrate selection and proper orientation of the peptide substrate in the active site (johnson2023anatlasof pages 3-4, johnson2023anatlasof pages 4-4). Although a comprehensive consensus sequence exclusive to CDK3 has not been fully delineated in the current literature, the S/T-P motif underlies the mechanistic basis for substrate recognition across many cyclin-dependent kinases, ensuring that CDK3 phosphorylates only select proteins integral to the regulation of cell cycle checkpoints and transcription.
5. Structure  
   The structural organization of CDK3 adheres to the canonical features observed in cyclin-dependent kinases. Its central component is a conserved kinase domain that is typically about 250–300 amino acids in length and is organized into two main lobes: an N-terminal lobe and a larger C-terminal lobe (wood2018structuralinsightsinto pages 1-2, klenor2021rationaldesignof pages 13-16). The N-terminal lobe, enriched in β-sheets, contains the glycine-rich loop crucial for ATP binding. This loop is a key element that allows CDK3 to position the nucleotide correctly within the active site. In addition, the N-terminal lobe harbors the PSTAIRE helix, which is essential for the binding of cyclin-C—a critical interaction that drives the activation of CDK3 (wood2018structuralinsightsinto pages 1-2). The larger C-terminal lobe is predominantly helical and includes the activation loop (T-loop), where phosphorylation events are known to trigger conformational rearrangements resulting in full kinase activation (klenor2021rationaldesignof pages 34-36). Structural models derived from homologous kinases, such as CDK2, indicate that CDK3 most likely contains well-conserved residues in motifs such as HRD (His-Arg-Asp) and DFG (Asp-Phe-Gly) that are indispensable for catalytic turnover and proper substrate orientation (wood2018structuralinsightsinto pages 20-20, klenor2021rationaldesignof pages 34-36). Although high-resolution crystal structures for CDK3 are not yet widely available, recent computational studies using tools like AlphaFold have begun to shed light on the three-dimensional arrangement of the active site. These models reaffirm the overall bilobal structure of CDK3 while also indicating subtle structural variations in the cyclin-binding interface that may explain its preferential interaction with cyclin-C during interphase (pellarin2025cyclindependentproteinkinases pages 51-52, pluta2024investigatingtherole pages 291-294). Such structural nuances not only underpin CDK3’s catalytic activity but also differentiate its functional behavior from other CDKs with overlapping roles in cell cycle control.
6. Regulation  
   CDK3 is regulated by a multifaceted network of mechanisms that ensure its activity is precisely coordinated with the cell cycle. The primary regulatory event is its association with cyclin-C (CCNC), which is indispensable for initiating the conformational changes necessary to open the active site and permit substrate binding (alrouji2025mechanisticrolesof pages 1-2, chowdhury2023cmgckinasesin pages 4-6). In isolation, CDK3 remains in a relatively inactive state; however, upon binding cyclin-C, its structure rearranges to allow efficient ATP binding and subsequent phosphorylation reactions. In addition to cyclin association, phosphorylation of CDK3’s activation loop (T-loop) by CDK-activating kinases (CAKs) is believed to be crucial for achieving full catalytic competence (klenor2021rationaldesignof pages 34-36, nilapwar2009characterizationandexploitation pages 47-51). Although specific phosphorylation sites on CDK3 have not been exhaustively mapped in the current literature, insights drawn from related CDKs suggest that such phosphorylation fosters a conformational transition that stabilizes the active site. Further regulation of CDK3 may also occur through post-translational modifications such as ubiquitination, which can target the protein for proteasomal degradation once its role in facilitating the G0-to-G1 transition has been fulfilled; this process prevents unwarranted kinase activity that might lead to aberrant cell cycle progression (chowdhury2023cmgckinasesin pages 2-4, pluta2024cyclin‐dependentkinasesmasters pages 12-14). In addition, the interplay with cyclin-dependent kinase inhibitors (CKIs)—although not as well characterized for CDK3 as for other family members—provides an extra layer of negative regulation, thereby ensuring that CDK3 activity is tightly synchronized with cellular proliferation needs (dowerah2025identificationofeffective pages 68-71). Together, these regulatory mechanisms—cyclin binding, activation loop phosphorylation, and targeted degradation—secure CDK3’s pivotal role during the early phases of cell cycle re-entry.
7. Function  
   CDK3 functions as a pivotal regulator of cell cycle re-entry and progression, primarily orchestrating the transitions from the quiescent G0 state into the proliferative G1 phase and facilitating progression into the S phase. One of the most significant functions of CDK3 is its ability to phosphorylate the retinoblastoma protein (RB1). This phosphorylation – mediated by the CDK3/cyclin-C complex – results in the inactivation of RB1’s repressive effects on E2F transcription factors, effectively licensing the transcriptional programs required for DNA synthesis and cell cycle progression (alrouji2025mechanisticrolesof pages 1-2, pellarin2025cyclindependentproteinkinases pages 51-52). In addition to RB1, CDK3 phosphorylates ATF1, a transcription factor whose activation leads to enhanced transactivation of genes that promote cellular proliferation and transformation (pellarin2025cyclindependentproteinkinases pages 2-4). This dual role—targeting both cell cycle regulators like RB1 and transcriptional modulators such as ATF1—positions CDK3 as a bifunctional integrator, linking cell cycle progression with the modulation of gene expression. Furthermore, evidence suggests that CDK3 might also contribute to the G1-S transition independently of RB1 by promoting the activation of E2F family members (specifically E2F1, E2F2 and E2F3), thereby reinforcing the transcriptional upregulation of genes essential for S phase entry (pellarin2025cyclindependentproteinkinases pages 9-10, hunter2015theeukaryoticprotein pages 1-3). Expression studies indicate that CDK3 is predominantly active during interphase, correlating with its functional role in facilitating the exit from quiescence and the initiation of DNA replication. This central function is particularly pertinent in tissues requiring rapid regeneration, as well as in oncogenic contexts where dysregulated CDK3 activity may drive uncontrolled cell proliferation and tumor progression (pluta2024investigatingtherole pages 60-62, sabri2024insightsintocyclindependent pages 27-30). Thus, CDK3 serves as a key modulator not only of cell cycle checkpoints but also of transcription-driven proliferative programs.
8. Other Comments  
   Recent studies have underscored the potential of CDK3 as a promising therapeutic target, particularly in the context of oncology. Multi-level computational screening has identified candidate inhibitors that selectively target the ATP-binding pocket of CDK3, offering a more refined alternative to broad-spectrum CDK inhibitors such as dinaciclib (dowerah2025identificationofeffective pages 68-71, fischer2004thedesignof pages 1-2). While inhibitors originally developed for other CDKs may exhibit cross-reactivity with CDK3, there remains a pressing need for compounds with enhanced specificity to minimize off-target effects. Moreover, integrative omics approaches that combine transcriptomic and epigenomic data have begun to reveal that even under-characterized kinases like CDK3 can serve as valuable prognostic markers or diagnostic targets in various cancers (southekal2021integrativeanalysisof pages 120-124). Current research is also focused on employing advanced phospho-proteomic techniques and proximity labeling strategies to expand our understanding of the CDK3 substrate repertoire and elucidate its role within complex signaling networks. Although direct disease-associated mutations in CDK3 have not been well documented, its central role in permitting G0-to-G1 and G1-to-S transitions implies that dysregulation of CDK3 activity could contribute to oncogenic transformation. Future research aimed at detailed structural elucidation, kinetic characterization and the development of selective inhibitors will be essential to fully exploit the therapeutic potential of CDK3. Furthermore, ongoing studies are expected to provide deeper insights into regulatory mechanisms such as post-translational modifications and protein–protein interactions that modulate CDK3 activity during cellular stress and differentiation responses (sharp2024manuscriptwithfigures. pages 6-10).
9. References  
   alrouji2025mechanisticrolesof pages 1-2; chowdhury2023cmgckinasesin pages 1-2; chowdhury2023cmgckinasesin pages 2-4; chowdhury2023cmgckinasesin pages 4-6; dowerah2025identificationofeffective pages 68-71; klenor2021rationaldesignof pages 1-8; klenor2021rationaldesignof pages 13-16; nilapwar2009characterizationandexploitation pages 47-51; pellarin2025cyclindependentproteinkinases pages 2-4; pellarin2025cyclindependentproteinkinases pages 51-52; pellarin2025cyclindependentproteinkinases pages 9-10; pluta2024cyclin‐dependentkinasesmasters pages 1-3; pluta2024cyclin‐dependentkinasesmasters pages 12-14; pluta2024investigatingtherole pages 291-294; prevel2015developmentoffluorescent pages 20-26; wang2023functionsofinteractions pages 17-23; wood2018structuralinsightsinto pages 1-2; wood2018structuralinsightsinto pages 20-20; adams2001kineticandcatalytic pages 2-3; bradley2019evolutionofprotein pages 1-2; bradley2019evolutionofprotein pages 2-3; chowdhury2023cmgckinasesin pages 8-9; fischer2004thedesignof pages 1-2; hunter2015theeukaryoticprotein pages 1-3; hunter2015theeukaryoticprotein pages 3-6; johnson2023anatlasof pages 1-2; johnson2023anatlasof pages 3-4; johnson2023anatlasof pages 4-4; johnson2023anatlasof pages 4-5; klenor2021rationaldesignof pages 34-36; pluta2024cyclin‐dependentkinasesmasters pages 49-49; pluta2024investigatingtherole pages 19-24; sharp2024manuscriptwithfigures. pages 6-10; southekal2021integrativeanalysisof pages 120-124.

References

1. (alrouji2025mechanisticrolesof pages 1-2): Mohammad Alrouji, Mohammed S. Alshammari, Saleha Anwar, Kumar Venkatesan, and Anas Shamsi. Mechanistic roles of transcriptional cyclin-dependent kinases in oncogenesis: implications for cancer therapy. Cancers, May 2025. URL: https://doi.org/10.3390/cancers17091554, doi:10.3390/cancers17091554. This article has 0 citations and is from a peer-reviewed journal.
2. (chowdhury2023cmgckinasesin pages 1-2): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
3. (chowdhury2023cmgckinasesin pages 2-4): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
4. (chowdhury2023cmgckinasesin pages 4-6): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
5. (dowerah2025identificationofeffective pages 68-71): D Dowerah, S Neog, N Biswakarma, and P Dutta. Identification of effective cyclin-dependent kinase 3/cyclin e inhibitors using multi-level computational screening and simulation. Unknown journal, 2025.
6. (klenor2021rationaldesignof pages 1-8): M Klenor. Rational design of cyclin-dependent kinase inhibitors. Unknown journal, 2021.
7. (klenor2021rationaldesignof pages 13-16): M Klenor. Rational design of cyclin-dependent kinase inhibitors. Unknown journal, 2021.
8. (nilapwar2009characterizationandexploitation pages 47-51): S Nilapwar. Characterization and exploitation of protein ligand interactions for structure based drug design. Unknown journal, 2009.
9. (pellarin2025cyclindependentproteinkinases pages 2-4): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 20 citations and is from a peer-reviewed journal.
10. (pellarin2025cyclindependentproteinkinases pages 51-52): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 20 citations and is from a peer-reviewed journal.
11. (pellarin2025cyclindependentproteinkinases pages 9-10): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 20 citations and is from a peer-reviewed journal.
12. (pluta2024cyclin‐dependentkinasesmasters pages 1-3): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.
13. (pluta2024cyclin‐dependentkinasesmasters pages 12-14): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.
14. (pluta2024investigatingtherole pages 291-294): AJ Pluta. Investigating the role of cdk1 in governing the transcriptional landscape in cancer cells. Unknown journal, 2024.
15. (prevel2015developmentoffluorescent pages 20-26): C Prevel. Development of fluorescent biosensors and inhibitors to probe and target cdk4/cyclin d in melanoma. Unknown journal, 2015.
16. (wang2023functionsofinteractions pages 17-23): X Wang. Functions of interactions and localization of ankle2 during mitosis. Unknown journal, 2023.
17. (wood2018structuralinsightsinto pages 1-2): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 264 citations and is from a peer-reviewed journal.
18. (wood2018structuralinsightsinto pages 20-20): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 264 citations and is from a peer-reviewed journal.
19. (adams2001kineticandcatalytic pages 2-3): Joseph A. Adams. Kinetic and catalytic mechanisms of protein kinases. Chemical Reviews, 101:2271-2290, Jul 2001. URL: https://doi.org/10.1021/cr000230w, doi:10.1021/cr000230w. This article has 860 citations and is from a highest quality peer-reviewed journal.
20. (bradley2019evolutionofprotein pages 1-2): David Bradley and Pedro Beltrao. Evolution of protein kinase substrate recognition at the active site. PLOS Biology, 17:e3000341, Jun 2019. URL: https://doi.org/10.1371/journal.pbio.3000341, doi:10.1371/journal.pbio.3000341. This article has 75 citations and is from a highest quality peer-reviewed journal.
21. (bradley2019evolutionofprotein pages 2-3): David Bradley and Pedro Beltrao. Evolution of protein kinase substrate recognition at the active site. PLOS Biology, 17:e3000341, Jun 2019. URL: https://doi.org/10.1371/journal.pbio.3000341, doi:10.1371/journal.pbio.3000341. This article has 75 citations and is from a highest quality peer-reviewed journal.
22. (chowdhury2023cmgckinasesin pages 8-9): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
23. (fischer2004thedesignof pages 1-2): PM Fischer. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Current Medicinal Chemistry, 11:1563-1583, Jun 2004. URL: https://doi.org/10.2174/0929867043365062, doi:10.2174/0929867043365062. This article has 160 citations and is from a peer-reviewed journal.
24. (hunter2015theeukaryoticprotein pages 1-3): Tony Hunter and Gerard Manning. The eukaryotic protein kinase superfamily and the emergence of receptor tyrosine kinases. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease, pages 1-15, Oct 2015. URL: https://doi.org/10.1007/978-1-4939-2053-2\_1, doi:10.1007/978-1-4939-2053-2\_1. This article has 6 citations.
25. (hunter2015theeukaryoticprotein pages 3-6): Tony Hunter and Gerard Manning. The eukaryotic protein kinase superfamily and the emergence of receptor tyrosine kinases. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease, pages 1-15, Oct 2015. URL: https://doi.org/10.1007/978-1-4939-2053-2\_1, doi:10.1007/978-1-4939-2053-2\_1. This article has 6 citations.
26. (johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
27. (johnson2023anatlasof pages 3-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
28. (johnson2023anatlasof pages 4-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
29. (johnson2023anatlasof pages 4-5): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
30. (klenor2021rationaldesignof pages 34-36): M Klenor. Rational design of cyclin-dependent kinase inhibitors. Unknown journal, 2021.
31. (pluta2024cyclin‐dependentkinasesmasters pages 49-49): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.
32. (pluta2024investigatingtherole pages 19-24): AJ Pluta. Investigating the role of cdk1 in governing the transcriptional landscape in cancer cells. Unknown journal, 2024.
33. (pluta2024investigatingtherole pages 60-62): AJ Pluta. Investigating the role of cdk1 in governing the transcriptional landscape in cancer cells. Unknown journal, 2024.
34. (sabri2024insightsintocyclindependent pages 27-30): RSM Sabri. Insights into cyclin-dependent kinases and their roles in neutrophil dynamics. Unknown journal, 2024.
35. (sharp2024manuscriptwithfigures. pages 6-10): AK Sharp and MB Anne. Manuscript with figures. pdf. Unknown journal, 2024.
36. (southekal2021integrativeanalysisof pages 120-124): S Southekal. Integrative analysis of multi-omics kinome data and virtual screening of identified targets with pan-cancer application. Unknown journal, 2021.